Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different types of tumors, leading to improvement in survival, even in patients with advanced cancers. Despite the good clinical results, a certain percentage of patients do not respond to this kind of immunotherapy. In...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Exp Clin Cancer Res
Hlavní autoři: Camelliti, Simone, Le Noci, Valentino, Bianchi, Francesca, Moscheni, Claudia, Arnaboldi, Francesca, Gagliano, Nicoletta, Balsari, Andrea, Garassino, Marina Chiara, Tagliabue, Elda, Sfondrini, Lucia, Sommariva, Michele
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650183/
https://ncbi.nlm.nih.gov/pubmed/33168050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-01721-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky